CELYAD ONCOLOGY (CYAD.BR) Stock Cash Flow
Europe - Euronext Brussels - EBR:CYAD - BE0974260896 - Common Stock
0.2 EUR
0 (-1.96%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -6.45M | -5.82M | -8.45M | -40.88M | -26.51M | |||
| Depreciation Amortization | 425.00K | 450.00K | 794.00K | 1.44M | 1.52M | |||
| Change In Working Capital | -78.00K | -159.00K | -6.45M | -1.84M | 1.43M | |||
| Other non cash items | -16.00K | -147.00K | -1.10M | 13.27M | -3.08M | |||
| OPERATING CASH FLOW | -6.12M | -5.68M | -15.20M | -28.01M | -26.64M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | N/A | -118.00K | -934.00K | -123.00K | -393.00K | |||
| Other Investing Activity | N/A | 15.00K | 1.34M | 7.33M | 267.00K | |||
| INVESTING CASH FLOW | N/A | -103.00K | 407.00K | 7.20M | -126.00K | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -157.00K | -167.00K | -145.00K | -1.02M | -1.14M | |||
| Stock Issued/Repurchased | N/A | N/A | 9.49M | N/A | 36.57M | |||
| Other Financing Activity | 829.00K | 3.15M | 10.00K | 4.26M | 4.09M | |||
| FINANCING CASH FLOW | 672.00K | 2.98M | 9.36M | 3.24M | 39.52M | |||
| Exchange Rate Effect | -3.00K | -4.00K | -1.00K | -6.00K | 32.00K | |||
| CHANGE IN CASH | -5.44M | -2.80M | -5.44M | -17.57M | 12.78M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -6.12M | -5.68M | -15.20M | -28.01M | -26.64M | |||
| Capital Expenditure | N/A | -118.00K | -934.00K | -123.00K | -393.00K | |||
| FREE CASH FLOW | -6.12M | -5.80M | -16.14M | -28.13M | -27.04M | |||
All data in EUR